Observational studyJournal of medical virology2026
Viral Landscape, Clinical Impact, and Management Trends in Hospitalized Children for Viral-Associated Lower Respiratory Tract Diseases: A Comparative Analysis of Two Post-Pandemic Seasons in Rome, Italy.
Observational study in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After the COVID-19 emergency, respiratory viruses have re-emerged with changing and region-specific patterns. We aimed to characterize how these shifts affected viral circulation, clinical severity, and management of pediatric viral-associated lower respiratory tract disease (LRTD)across two post-pandemic seasons in Rome, Italy. We conducted a retrospective observational study of children (< 6 years) hospitalized with PCR-confirmed viral LRTDs during the 2022-2023 and 2023-2024 seasons. Of the 1,249 children hospitalized for LRTD, 49.08% were admitted during the 2022-2023 season and 50.92% during the 2023-2024 season. Clinical severity at presentation (PRESS ≥ 4) did not differ between the two seasons; however, a severe in-hospital course (CSS > 3) was more frequent in 2023-2024 (8.96% vs. 4.24%; p = 0.001). In 2023-2024, the corticosteroid use increased (77.20% vs. 72.43%; p = 0.05), whereas antibiotic use decreased (47.80% vs. 39.78%; p = 0.004). Respiratory syncytial virus remained the most common pathogen in both seasons, with no significant variation between them. Similarly, influenza showed no significant difference in prevalence. Compared with 2022-2023, 2023-2024 showed a higher prevalence of rhinovirus (50.31% vs. 37.36%), enterovirus (24.53% vs. 15.82%), bocavirus (13.99% vs. 8.16%) and viral codetection (51.89% vs. 45.02%) while adenovirus was more frequent in 2022-2023 (7.39% vs. 13.21%). Multivariable analysis identified the 2023-2024 season (OR 2.37; 95% CI 1.45-3.87), younger age (OR 0.96 per month; 95% CI 0.94-0.98), and comorbidities (OR 2.91; 95% CI 1.66-5.11) as independent predictors of severe in-hospital course. Male sex, viral codetection, and viral clinical categories were not associated with severity. In conclusion, in Rome's regional context, the evolving viral ecology highlights the need for continued local surveillance to guide clinical preparedness and optimize management in forthcoming seasons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.